Alamar Biosciences, Inc.
Alamar Biosciences, Inc.
Your view on ALMR
Overview
What the company does, where it operates, and who runs it.
About Alamar Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yuling Luo
- Headquarters
- 47071 Bayside Parkway, Fremont, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yuling Luo
- Headquarters
- 47071 Bayside Parkway, Fremont, CA, US
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications.
Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Alamar Biosciences, Inc. from FRC's valuation model, read against the market price. ALMR last traded at $30.51; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Alamar Biosciences, Inc.. Starting points for Alamar Biosciences, Inc.: EPS -$0.80, beta -6.18 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Alamar Biosciences, Inc.. Alamar Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Alamar Biosciences, Inc.. Trailing twelve-month EPS for Alamar Biosciences, Inc. stands at -$0.80. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Alamar Biosciences, Inc.. Alamar Biosciences, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Biotechnology companies
Market cap
- ARUXFAcrux LimitedOTC$2M
- ARVNArvinas, Inc.NASDAQ$443M
- ARWRArrowhead Pharmaceuticals, Inc.NASDAQ$6.1B
- ASBPAspire Biopharma Holdings, Inc.NASDAQ$910,285
- ASBPWAspire Biopharma Holdings, Inc.NASDAQ$121,920
- ASCLFAscletis Pharma Inc.OTC$2.1B
- ASEP.CNAsep Medical Holdings IncCNQ
- ASMBAssembly Biosciences, Inc.NASDAQ$458M
- ASNDAscendis Pharma A/SNASDAQ$17.7B
- ASPHFAscentage Pharma Group InternationalOTC$3.2B
- ATAIAtai Life Sciences N.V.NASDAQ$2.7B
- ATGGFActinogen Medical LimitedOTC$108M
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Alamar Biosciences, Inc., and how their positions are changing. At a $2.12B market value, institutional positions materially move Alamar Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Alamar Biosciences, Inc. executives and directors. Shares of Alamar Biosciences, Inc. have traded between $18.85 and $29.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Alamar Biosciences, Inc.. Coverage tracks Alamar Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Alamar Biosciences, Inc.